Search results
Geron Corporation's (NASDAQ:GERN) large institutional owners must be happy as stock continues to...
Simply Wall St. via Yahoo Finance· 20 hours agoThe group holding the most number of shares in the company, around 61% to be precise, is...
Geron (GERN) Wins FDA Approval for Blood Cancer Drug, Stock Up
Zacks via Yahoo Finance· 4 days agoGeron's (GERN) shares rise on approval of its first drug. The FDA approves imetelstat for the...
Geron Co. (NASDAQ:GERN) EVP Faye Feller Sells 287,900 Shares of Stock
ETF DAILY NEWS· 24 hours agoGeron Co. (NASDAQ:GERN – Get Free Report) EVP Faye Feller sold 287,900 shares of the company’s stock in a transaction dated Monday, June 10th. Geron Co. has a 12 month low ...
Why Is Geron (GERN) Stock Up 18% Today?
InvestorPlace· 7 days agoGeron (NASDAQ:GERN) stock is heading higher on Friday after getting approval from the U.S. Food and Drug Administration (FDA) for RYTELO. RYTELO is the...
Geron (NASDAQ:GERN) Now Covered by Analysts at Barclays
ETF DAILY NEWS· 4 days agoEquities researchers at Barclays started coverage on shares of Geron (NASDAQ:GERN – Get Free Report) in a research note issued to investors on Monday, Benzinga reports. The ...
Very good news for Geron stock price: now what? | Invezz
Invezz· 7 days agoGeron Corporation (NASDAQ: GERN) stock price went vertical on Friday as investors cheered the latest...
Geron stock steady as analysts maintain 'buy' rating with $10 target By Investing.com
Investing.com· 7 days agoOn Friday, TD (TSX:TD) Cowen reaffirmed its confidence in Geron (NASDAQ:GERN) Corporation (NASDAQ:...
FDA Approves Geron's First Commercial Drug, Competes With Bristol Myers Squibb's Blood Cancer Drug
Benzinga via Yahoo Finance· 7 days agoOn Thursday, the FDA approved Geron Corporation's (NASDAQ:GERN) Rytelo (imetelstat) for adult...
Is Geron Stock a Buy Following Its First New Drug Approval?
Motley Fool via Yahoo Finance· 6 days agoShares of Geron (NASDAQ: GERN) finished the week ended June 7 about 32% higher. The market was...
Geron Corp stock opened 25% up on Friday: here's why | Invezz
Invezz· 7 days agoAre you looking for signals & alerts from pro-traders? The Food & Drug Administration approved its lead asset as a late-line treatment for myelodysplastic syndromes (MDS). The telomerase inhibitor ...